JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, H.
Right arrow Articles by Visner, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, H.
Right arrow Articles by Visner, G. A.
Related Collections
Right arrow Lung - transplantation

J Thorac Cardiovasc Surg 2005;130:852-858
© 2005 The American Association for Thoracic Surgery


Cardiothoracic Transplantation

Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model

Hanzhong Liu, MD, PhD a , * , Peter Drew, MD b , Yanping Cheng, BA a , Gary A. Visner, DO a

a Department of Pediatrics University of Florida, Gainesville, Fla
b Department of Pathology University of Florida, Gainesville, Fla

Received for publication January 28, 2005; revisions received March 29, 2005; accepted for publication April 18, 2005.

* Address for reprints: Gary A. Visner, DO, Box 100296, 1600 SW Archer, Department of Pediatrics, University of Florida, Gainesville, FL 32610 (Email: visnerga{at}peds.ufl.edu).

OBJECTIVE: Tumor necrosis factor {alpha} is a proinflammatory cytokine that has been proved to play a crucial role in inducing posttransplantation lung injury. The present study was performed to determine whether pirfenidone, a new nonpeptide drug with potent anti–tumor necrosis factor {alpha} activity, promotes protection against acute allograft injury through inhibiting pulmonary inflammatory responses in a rat model of orthotopic lung transplantation.

METHODS: Three transplant groups were formed: isografts, untreated allografts, and allografts treated with pirfenidone (0.5% chow starting on day 1 after transplantation). The implants were harvested on day 21 after transplantation. Acute cellular rejection grade and degree of allograft injury were evaluated on the basis of hematoxylin-and-eosin staining. The pulmonary inflammatory response and inflammation-induced oxidative stress were assessed on the basis of neutrophil accumulation (myeloperoxidase immunoreactivity and enzymatic activity) and iron deposition (Prussian blue staining). In addition, circulating levels of tissue necrosis factor {alpha} in all animals were measured.

RESULTS: The degree of allograft injury was significantly reduced in pirfenidone-treated allografts relative to untreated allografts (P < .01). The beneficial effect of pirfenidone was associated with decreased lung myeloperoxidase immunoreactivity (P < .05) and enzymatic activity (P < .01). Moreover, the untreated allografts contained a high concentration of iron, which was strikingly reduced by pirfenidone. Treatment with pirfenidone resulted in a lower level of plasma tissue necrosis factor {alpha}, which correlated positively with lung myeloperoxidase enzymatic activity (P < .0001).

CONCLUSION: These results suggest that pirfenidone, with its anti–tissue necrosis factor {alpha} activity, reduced neutrophil recruitment and iron accumulation, hence limiting the acute lung allograft injury.





This article has been cited by other articles:


Home page
J. Immunol.Home page
H. Liu, L. Liu, K. Liu, P. Bizargity, W. W. Hancock, and G. A. Visner
Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression
J. Immunol., July 15, 2009; 183(2): 1022 - 1031.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
S. Shi, J. Wu, H. Chen, H. Chen, J. Wu, and F. Zeng
Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers
J. Clin. Pharmacol., October 1, 2007; 47(10): 1268 - 1276.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. Liu, L. Liu, B. S. Fletcher, and G. A. Visner
Novel Action of Indoleamine 2,3-Dioxygenase Attenuating Acute Lung Allograft Injury
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 566 - 572.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.